Key facts
- It has raised $3.1M; the latest was Early Stage VC ($2.5M) in Dec 2025.
- Notable investors include Venture Kick, Kickfund, Zürcher Kantonalbank, BaseLaunch, David Urech — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Aukera Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Aukera Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aukera Therapeutics
Developer of a pharmaceutical drug discovery engine designed to develop selective Mammalian targets of rapamycin (mTOR) complex inhibitors. The company's system develops drugs that selectively target different branches of the pathway, enabling medical practitioners to cure cancer and neurodegenerative diseases and keep the cell's growth engine in check.
- Sector
- Healthcare
- HQ
- Basel, Switzerland
- Founded
- 2021
- Employees
- 6
- Website
- aukera-tx.com/
- Ownership
- Privately Held (backing)
Aukera Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aukera Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aukera Therapeutics in its N-PORT filings yet. We sweep new filings monthly.